The 60 references in paper L. Shul'zhenko V., E. Bolotova V., Л. Шульженко В., Е. Болотова В. (2015) “Эффективность и безопасность агонистов #b2-адренорецепторов ультрадлительного действия // Efficacy and safety of long-acting beta-2-agonists” / spz:neicon:pulmonology:y:2015:i:1:p:113-118

1
Cazzola M., Page C.P., Rogliani P., Matera M.G. β2\nagonist therapy in lung disease. Am. J. Respir. Crit. Care Med.2013; 187 (7): 690–696.
(check this in PDF content)
2
Spina D. Current and novel bronchodilators in respiratory dis\n ease. Curr. Opin. Pulm. Med. 2014; 20 (1): 73–86.
(check this in PDF content)
3
Battram C., Charlton S.J., Cuenoud B. et al. In vitro and in vivo pharmacological characterization of 5\n[(R)\n2\n(5,6\n diethyl\nindan\n2\nylamino)\n1\nhydroxy\nethyl]\n8\nhydroxy\n1H'\n quinolm\n2\none (indacaterol), a novel inhaled β2\nadrenoceptor agonist with a 24\nh duration of action. J. Pharmacol. Exp. Ther.2006; 317: 762–770.
(check this in PDF content)
4
Sturton R.G., Trifilieff A., Nicholson A.G., Barnes P.J. Pharmacological characterization of indacaterol, a novel once daily inhaled β2\nadrenoceptor agonist, on small airways in human and rat precision\ncut lung slices. J. Pharmacol. Exp. Ther. 2008; 324: 270–275.
(check this in PDF content)
5
Naline E., Trifilieff A., Fairhurst R.A. et al. Effect of inda\n caterol, a novel long acting β2\nagonist, on isolated human bronchi. Eur. Respir. J. 2007; 29: 575–581.
(check this in PDF content)
6
Rosethorne E.M., Turner R.J., Fairhurst R.A., Charlton S.J. Efficacy is a contributing factor to the clinical onset of bron\n chodilation of inhaled β2\nadrenoceptor agonists. Naunyn. Schmiedebergs Arch. Pharmacol. 2010; 382: 255–263.
(check this in PDF content)
7
Cazzola M., Calzetta L., Page C.P., Matera M.G. Use of inda\n caterol for the treatment of COPD: a pharmacokinetic evalua\n tion. Exp. Opin. Drug Metab. Toxicol. 2014; 10 (1): 129–137.
(check this in PDF content)
8
Renard D., Looby M., Kramer B. et al. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model\nbased approaches. Respir. Res. 2011; 12: 54.
(check this in PDF content)
9
O'Donnell D.E., Casaburi R., Vincken W. et al. Effect of inda\n caterol on exercise endurance and lung hyperinflation in COPD. Respir. Med.2011; 105: 1030–1036.
(check this in PDF content)
10
Rossi A., Polese G. Indacaterol: a comprehensive review. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 353–363.
(check this in PDF content)
11
Cope S., Capkun\nNiggli G., Gale R. et al. Comparative effica\n cy of indacaterol 150 / xg and 300 / xg versus fixed\ndose com\n binations of formoterol + budesonide or salmeterol + fluticas\n one for the treatment of chronic obstructive pulmonary dis\n ease – a network meta\nanalysis. Int. J. Chron. Obstruct. Pulm. Dis.2011; 6: 329–344.
(check this in PDF content)
12
Singh M.P. Indacaterol therapy in moderate\nto\nsevere chronic obstructive pulmonary disease: findings from a single\ncenter primary care cohort.Int. J. Chron. Obstruct. Pulm. Dis.2013; 8: 613–619.
(check this in PDF content)
13
Ridolo E., Montagni M., Olivieri E. et al. Role of indacaterol and the newer very long\nacting β2\nagonists in patients with sta\n ble COPD: A review. Int. J. Chron. Obstruct. Pulm. Dis.2013; 8: 425–432.
(check this in PDF content)
14
Chowdhury B.A., Dal Pan G. The FDA and safe use of long\n acting beta\nagonists in the treatment of asthma. N. Engl. J. Med.2010; 362: 1169–1171.
(check this in PDF content)
15
Kanniess F., Boulet L.P., Pierzchala W. et al. Efficacy and safe\n ty of indacaterol, a new 24\nh β2\nagonist, in patients with asth\n ma: a dose\nranging study. J. Asthma. 2008; 45: 887–892.
(check this in PDF content)
16
La Force C., Alexander M., Deckelmann R. et al. Indacaterol provides sustained 24 h bronchodilation on once\ndaily dosing in asthma: a 7\nday dose\nranging study. Allergy. 2008; 63: 103–111.
(check this in PDF content)
17
Chowdhury B.A., Seymour S.M., Levenson M.S. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N. Engl. J. Med.2011; 364: 2473–2475.
(check this in PDF content)
18
Cazzola M., Segreti A., Matera M.G. Novel bronchodilators in asthma.Curr. Opin. Pulm. Med. 2010; 16: 6–12.
(check this in PDF content)
19
Bouyssou T., Casarosa P., Naline E. et al. Pharmacological characterization of olodaterol, a novel inhaled β2\nadrenocep\n tor agonist exerting a 24\nhour\nlong duration of action in pre\n clinical models. J. Pharmacol. Exp. Ther. 2010; 334: 53–62.
(check this in PDF content)
20
McKeage K. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs. 2012; 72 (4): 543–563.
(check this in PDF content)
21
Naline E., Ostermann A., Devillier P., Casarosa P. β2\nagonist intrinsic activity: comparison of BI 1744 and formoterol in dif\n ferent functional settings.Am. J. Respir. Crit. Care Med.2010; 181: A4443.
(check this in PDF content)
22
Gibb A., Yang L.P. Olodaterol: first global approval. Drugs. 2013; 73 (16): 1841–1846.
(check this in PDF content)
23
Brown S.M., Barnes P.J., Donnelly L.E. Effect of olodaterol on the relaxation of small airways. Eur. Respir. J.2011; 38: 308s.
(check this in PDF content)
24
Casarosa P., Kollak I., Kiechle T. et al. Functional and bio\n chemical rationales for the 24\nhour\nlong duration of action of olodaterol.J. Pharmacol. Exp. Ther.2011; 337: 600–609.
(check this in PDF content)
25
Noord J.A., Smeets J.J., Drenth B.M. et al. 24\nHour bron\n chodilation following a single dose of the novel β2\nagonist olo\n daterol in COPD. Pulm. Pharmacol. Ther. 2011; 24: 666–672.
(check this in PDF content)
26
Procopiou P.A., Barrett V.J., Bevan N.J. et al. Synthesis and structure\nactivity relationships of long\nacting β2\nadrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.J. Med. Chem. 2010; 53: 4522–4530.
(check this in PDF content)
27
Ferguson G.T., Feldman G.J., Hofbauer P. et al. Efficacy and safety of olodaterol once daily delivered via Respimat®in patients with GOLD 2–4 COPD: results from two replicate 48\nweek studies.Int. J. Chron. Obstruct. Pulm. Dis. 2014; 9: 629–645.
(check this in PDF content)
28
Costa L., Roth M., Miglino N. et al. Tiotropium sustains the anti\ninflammatory action of olodaterol via the cyclic AMP pathway. Pulm. Pharmacol. Ther. 2014; 27 (1): 29–37.
(check this in PDF content)
29
Barrett V.J., Emmons A., Ford A.J., Knowles R. In vitro phar\n macological characterisation of GW642444, a novel long acting β1\nagonist (LABA) using human recombinant β1/2/3\n adrenoceptor cAMP assays. Am. J. Respir. Crit. Care Med. 2010; 181: A4451.
(check this in PDF content)
30
Ford A.J., Hughes S., Morrison V.et al. In vitro and in vivo pharmacological characterisation of GW642444, a novel long\n acting β2\nagonist (LABA), with fast onset and long duration in the guinea\npig. Am. J. Respir. Crit. Care Med. 2010; 181: A5677.
(check this in PDF content)
31
Slack R.J., Barrett V.J., Morrison V.S. et al. In vitro pharma\n cological characterization of vilanterol, a novel long\nacting β2\nadrenoceptor agonist with 24\nhour duration of action. J. Pharmacol. Exp. Ther. 2013; 344 (1): 218–230.
(check this in PDF content)
32
Ford A.J., Hughes S., Smith C. et al. The therapeutic index of vilanterol trifenatate.Eur. Respir. J.2010; 24: 208s.
(check this in PDF content)
33
Kempsford R., Norris V., Siederer S. GW642444, a novel inhaled long\nacting β2\nadrenoceptor agonist (LABA), at single doses of 25, 50 and 100 mcg, is well tolerated and demonstrates prolonged bronchodilation in asthmatic patients.Am. J. Respir. Crit. Care Med. 2010; 181: A5413.
(check this in PDF content)
34
Kempsford R., Norris V., Siederer S. Vilanterol trifenatate, a novel inhaled long\nacting beta2\nadrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm. Pharmacol. Ther.2013; 26 (2): 256–264.
(check this in PDF content)
35
Kempsford R., Norris V., Siederer S. GW642444, a novel inhaled long\nacting β2\nadrenoceptor agonist (LABA), at single doses of 25, 50 and 100 mcg, is well tolerated and demonstrates prolonged bronchodilation in COPD patients. Am. J. Respir. Crit. Care Med.2010; 181: A4447.
(check this in PDF content)
36
Lotvall J., Bateman E.D., Bleecker E.R. et al. Dose\nrelated efficacy of vilanterol trifena\n tate, a long\nacting beta2 agonist with inherent 24\nhour activity, in patients with persistent asth\n ma. Eur. Respir. J.2010; 24: 1013s.
(check this in PDF content)
37
Lotvall J., Bateman E.D., Bleecker E.R. et al. 24\nh duration of the novel LABA vilanterol trifenatate in asthma patients treat\n ed with inhaled corticosteroids. Eur. Respir. J. 2012; 40 (3): 570–579.
(check this in PDF content)
38
Sterling R., Lim J., Frith L. et al. Dose\nrelated efficacy and optimal once\ndaily (OD) dosing interval of the long\nacting beta\n2\nagonist (LABA), vilanterol trifenatate (VI), in adults with persistent asthma. Am. J. Respir. Crit. Care Med.2011; 183: A4488.
(check this in PDF content)
39
Hanania N.A., Feldman G., Zachgo W. et al. The efficacy and safety of the novel long\nacting β2\nagonist vilanterol in COPD patients: a randomized placebo\ncontrolled trial. Chest. 2012; 142 (1): 119–127.
(check this in PDF content)
40
Kikkawa H., Naito K., Ikezawa K. Tracheal relaxing effects and β2\nselectivity of TA\n2005, a newly developed bronchodi\n lating agent, in isolated guinea\npig tissues. Jpn. J. Pharmacol. 1991; 57: 175–185.
(check this in PDF content)
41
Voss H.P., Donnell D., Bast A. Atypical molecular pharmacol\n ogy of a new long\nacting β2\nadrenoceptor agonist, TA\n2005. Eur. J. Pharmacol. 1992; 227: 403–409.
(check this in PDF content)
42
Standifer K.M., Pitha J., Baker S.P. Carbostyril\nbased β2\nad\n renergic agonists: evidence for long lasting or apparent irre\n versible receptor binding and activation of adenylate cyclase activity in vitro. Naunyn. Schmiedebergs Arch. Pharmacol. 1989; 339: 129–137.
(check this in PDF content)
43
Kikkawa H., Kanno K., Ikezawa K. TA\n2005, a novel, long\n acting and selective p2\nadrenocepter agonist: characterization of its in vivo bronchodilating action in guinea pigs and cats in comparison with other β2\nagonists. Biol. Pharm. Bull.1994; 17: 1047–1052.
(check this in PDF content)
44
Voss H.P. Long\nacting β2\nadrenoceptor agonists in asthma: molecular pharma\ncological aspects. Vrije Universiteit: Amsterdam; 1994.
(check this in PDF content)
45
Kikkawa H., Isogaya M., Nagao T., Kurose H. The role of the seventh transmembrane region in high affinity binding of aβ2\nselective agonist TA\n2005. Mol. Pharmacol.1998; 53: 128–134.
(check this in PDF content)
46
Cazzola M., Segreti A., Matera M.G. Novel bronchodilators in asthma. Curr. Opin. Pulm. Med.2010; 16: 6–12.
(check this in PDF content)
47
Haeussermann S., Acerbi A., Brand P. et al. Lung deposition of carmoterol in healthy subjects, patients with asthma and patients with COPD. Eur. Respir. J.2006; 28: 211s.
(check this in PDF content)
48
Kottakis I., Nandeuil A., Raptis H. et al. Efficacy of the novel very long\nacting β\nagonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma. Eur. Respir. J. 2006; 28: 665s.
(check this in PDF content)
49
Nandeuil A., Kottakis I., Raptis H. et al. Safety and tolerabili\n ty of the novel very long acting β2\nagonist carmoterol given as a 2 / xg qd dose; 8 days comparison with formoterol and place\n bo in patients with persistent asthma. Eur. Respir. J.2006; 28: 665s.
(check this in PDF content)
50
Kanniess F., Make B.J., Petruzzelli S. Acute effect of car\n moterol, a long\nacting β2\nagonist, in patients with COPD. Proc. Am. Thorac. Soc.2008; 5: A655.
(check this in PDF content)
51
Make B.J., Kanniess F., Bateman E.D., Linberg S.E. Efficacy of 3 different doses of carmoterol, a long\nacting β2\nagonist in patients with COPD. Proc. Am. Thorac. Soc. 2008; 5: A961.
(check this in PDF content)
52
Bateman E.D., Make B.J., Nandeuil M.A. Carmoterol – safe\n ty and tolerability of a long\nacting β2\nagonist in patients with COPD. Proc. Am. Thorac. Soc.2008; 5: A653.
(check this in PDF content)
53
Rossing T.H., Make B.J., Heyman E.R. Carmoterol does not induce tolerance in COPD. Proc. Am. Thorac. Soc. 2008; 5: A962.
(check this in PDF content)
54
Glossop P.A., Lane C.A., Price D.A. et al. Inhalation by design: novel ultra\nlong\nacting β2\nadrenoreceptor agonists for inhaled once\ndaily treatment of asthma and chronic obstruc\n tive pulmonary disease that utilize a sulfonamide agonist head\n group.J. Med. Chem. 2010; 53: 6640–6652.
(check this in PDF content)
55
Li G.L., Mac Intyre F., Surujbally B. et al. Pharmacokinetics of PF\n00610355, a novel inhaled long\nacting β2\nadrenorecep\n tor agonist. Eur. Respir. J.2009; 34: 777s.
(check this in PDF content)
56
Macintyre F., Jones I., Surujbally B. A randomised, double\n blind study to determine the duration of action of lung phar\n macodynamics by plethysmography (sGaw) of a β2\nadrenore\n ceptor agonist, PF\n00610355. Eur. Respir. J.2009; 34: 344s.
(check this in PDF content)
57
Ward J., Macintyre F., Jones I. et al. A randomised double\n blind, study to determine the efficacy & safety of a once\ndaily inhaled β2\nadrenoreceptor agonist, PF\n00610355 in asthmatic patients. Eur. Respir. J. 2009;34: 778s.
(check this in PDF content)
58
Diderichsen P.M., Cox E., Martin S.W. et al. Predicted heart rate effect of inhaled PF\n00610355, a long acting β\nadreno\n ceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease. Br. J. Clin. Pharmacol. 2013; 76 (5): 752–762.
(check this in PDF content)
59
Young A., Nicholls D., Connolly S. et al. The in vivo profile of AZD3199: a novel, fast acting β2\nagonist with a long duration of action (Abstract). Am. J. Respir. Crit. Care Med. 2011; 183: A1586.
(check this in PDF content)
60
Kuna P., Ivanov Y., Trofimov V. et al. Efficacy and safety of AZD3199, an inhaled ultra long\nacting β\nagonist, in patients with COPD. Eur. Respir. J. 2011; 38: 148s. Поступила 15.07.14 УДК 615.217.07
(check this in PDF content)